US Patent Issued to Novartis on July 14 for "Synthesis of prostate specific membrane antigen (PSMA) ligands" (Austrian Inventor)

ALEXANDRIA, Va., July 14 -- United States Patent no. 12,679,814, issued on July 14, was assigned to Novartis AG (Basel, Switzerland).

"Synthesis of prostate specific membrane antigen (PSMA) ligands" was invented by Fritz Andreae (Raaba-Grambach, Austria).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure relates to the synthesis of prostate specific membrane antigen (PSMA) ligands that are useful in the treatment of diseases like cancer. In particular, the disclosure relates to a method for synthesizing PSMA ligands having a glutamate-urea-lysine (GUL) moiety and a chelating agent that can comprise a radiometal."

The patent was filed on Nov. 19, 2021, under Application No. 18/253,298.

*Fo...